Randomized clinical trial of Vitamin D3 doses on prostatic Vitamin D metabolite levels and Ki67 labeling in prostate cancer patients

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages 1498-1507

  Wagner, Dennis ^a,b   Trudel, Dominique ^c   Van Der Kwast, Theodorus ^c   Nonn, Larisa ^d   Giangreco, Angeline Antonio ^d   Li, Doris ^b   Dias, Andre ^a,b   Cardoza, Monique ^c   Laszlo, Sanda ^c   Hersey, Karen ^c   Klotz, Laurence ^e   Finelli, Antonio ^c   Fleshner, Neil ^c   Vieth, Reinhold ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; COLECALCIFEROL; KI 67 ANTIGEN; PARATHYROID HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; CALCITRIOL BLOOD LEVEL; CALCITRIOL PROSTATE LEVEL; CANADA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; GLEASON SCORE; HUMAN; MALE; METABOLITE; MULTICENTER STUDY; PARATHYROID HORMONE BLOOD LEVEL; PATIENT SAFETY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TISSUE LEVEL; TUMOR GROWTH;

AGED; CARCINOMA; CHOLECALCIFEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; STAINING AND LABELING; TISSUE ARRAY ANALYSIS; VALIDATION STUDIES AS TOPIC; VITAMIN D;

EID: 84876269555     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-4019     Document Type: Article

References (42)

1. John EM, Schwartz GG, Koo J, Van Den Berg D, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res. 2005; 65(12): 5470-5479.
2. Robsahm TE, Tretli S, Dahlback A, Moan J. Vitamin D3 from sunlight may improve the prognosis of breast-, colon-and prostate cancer (Norway). Cancer Causes Control. 2004; 15(2): 149-158.
3. Vieth R, Choo R, Deboer L, Danjoux C, Morton GC, Klotz L. Rise in prostate-specific antigen in men with untreated low-grade prostate cancer is slower during spring-summer. Am J Ther. 2006; 13(5): 394-399.
4. Woo TC, Choo R, Jamieson M, Chander S, Vieth R. Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer. 2005; 51(1): 32-36.
5. Beer TM, Lemmon D, Lowe BA, Henner WD. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer. 2003; 97(5): 1217-1224.
6. Beer TM, Myrthue A, Garzotto M, et al. Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2004; 13(12): 2225-2232.
7. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol. 1998; 159(6): 2035-2039.
8. Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011; 29(16): 2191-2198.
9. Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer. 2006; 106(10): 2136-2142.
10. Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010; 16(1): 1-9.
11. Vieth R. The pharmacology of vitamin D, including fortification strategies. In: Feldman D, Glorieux FH, Pike JW, eds. Vitamin D. New York, NY: Elsevier Academic Press, 2005: 995-1018.
12. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010; 74(23): 1852-1859.
13. Kimball SM, Ursell MR, O'Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr. 2007; 86(3): 645-651.
14. Marshall DT, Savage SJ, Garrett-Mayer E, et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with lowrisk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012; 97(7): 2315-2324.
15. Barreto AM, Schwartz GG, Woodruff R, Cramer SD. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev. 2000; 9(3): 265-270.
16. Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1α,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res. 2000; 6(3): 901-908.
17. Tuohimaa P, Golovko O, Kalueff A, et al. Calcidiol and prostate cancer. J Steroid Biochem Mol Biol. 2005; 93(2-5):183-190.
18. 3 (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology. 2012; 153(6): 2576-2587.
19. Tokar EJ, Webber MM. Chemoprevention of prostate cancer by cholecalciferol (vitaminD3):25-hydroxylase (CYP27A1) inhuman prostate epithelial cells. Clin Exp Metastasis. 2005; 22(3): 265-273.
20. Tokar EJ, Webber MM. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin Exp Metastasis. 2005; 22(3): 275-284.
21. Wagner D, Dias AG, Schnabl K, Van der Kwast T, Vieth R. Determination of 1,25-dihydroxyvitamin D concentrations in human colon tissues and matched serum samples. Anticancer Res. 2012; 32(1): 259-263.
22. Wagner D, Sidhom G, Whiting SJ, Rousseau D, Vieth R. The bioavailability of vitamin D from fortified cheeses and supplements is equivalent in adults. J Nutr. 2008; 138(7): 1365-1371.
23. Wagner D, Hanwell HE, Schnabl K, et al. The ratio of serum 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) is predictive of 25-hydroxyvitamin D(3) response to vitamin D(3) supplementation. J Steroid Biochem Mol Biol. 2011; 126(3-5):72-77.
24. Mendel CM. The free hormone hypothesis. Distinction from the free hormone transport hypothesis. J Androl. 1992; 13(2): 107-116.
25. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994; 54(3): 805-810.
26. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993; 132(5): 1952-1960.
27. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182(3): 311-322.
28. Matkowskyj KA, Cox R, Jensen RT, Benya RV. Quantitative im-munohistochemistry by measuring cumulative signal strength accurately measures receptor number. J Histochem Cytochem. 2003; 51(2): 205-214.
29. Bruno S, Crissman HA, Bauer KD, Darzynkiewicz Z. Changes in cell nuclei during S phase: progressive chromatin condensation and altered expression of the proliferation-associated nuclear proteins Ki-67, cyclin (PCNA),p105, and p34. Exp Cell Res. 1991; 196(1): 99-106.
30. du Manoir S, Guillaud P, Camus E, Seigneurin D, Brugal G. Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment. Cytometry. 1991; 12(5): 455-463.
31. Starborg M, Gell K, Brundell E, Hoog C. The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression. J Cell Sci. 1996; 109(Pt 1):143-153.
32. Kovalenko PL, Zhang Z, Yu JG, Li Y, Clinton SK, Fleet JC. Dietary vitamin D and vitamin D receptor level modulate epithelial cell proliferation and apoptosis in the prostate. Cancer Prev Res (Phila). 2011; 4(10): 1617-1625.
33. Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB, DeLuca HF. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Invest. 1979; 64(3): 729-736.
34. Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL. Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr. 2001; 74(4): 549-554.
35. Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev. 1993; 2(5): 467-472.
36. Li H, Stampfer MJ, Hollis JB, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007; 4(3):e103.
37. Zeljic K, Supic G, Stamenkovic RM, Jovic N, Kozomara R, Magic Z. Vitamin D receptor, CYP27B1 and CYP24A1 genes polymorphisms association with oral cancer risk and survival. J Oral Pathol Med. 2012.
38. Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011; 377(9761): 242-250.
39. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003; 77(1): 204-210.
40. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr. 2001; 73(2): 288-294.
41. Schwartz GG, Hall MC, Stindt D, Patton S, Lovato J, Torti FM. Phase I/II study of 19-nor-1a-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res. 2005; 11(24 Pt 1):8680-8685.
42. Serpa NA, Tobias-Machado M, Esteves MA, et al. A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol. 2010; 10: 9.